Future advances in COPD therapy

Respiration

Volumn 68, Issue 5, 2001, Pages 441-448

  Barnes, Peter J ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 BROMOPHENYL) 3 (2 HYDROXY 4 NITROPHENYL)UREA; 1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; 2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 7 [3 [2 CYCLOPROPYLMETHYL 3 METHOXY 4 [(METHYLAMINO)CARBONYL]PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 PROPANOIC ACID; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BAMBUTEROL; BIIL 284; BRONCHODILATING AGENT; CHEMOKINE RECEPTOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; ENZYME INHIBITOR; GELATINASE INHIBITOR; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; LY 29311; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NITRONE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; PROTEIN INHIBITOR; RECOMBINANT INTERLEUKIN 10; SALMETEROL; SB 201146; THROMBOXANE RECEPTOR BLOCKING AGENT; TIOTROPIUM BROMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZILEUTON;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; GASTROINTESTINAL DISEASE; HUMAN; INHIBITION KINETICS; NAUSEA; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SMOKING CESSATION; TOXICITY; TREMOR;

DRUG THERAPY; FORECASTING; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING CESSATION;

EID: 0034756223     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000050547     Document Type: Review

References (67)

1. Chronic obstructive pulmonary disease
2. Mechanisms in COPD: Differences from asthma
3. New treatments for chronic obstructive pulmonary disease
4. Effectiveness of investigations to help people stop smoking: Findings from the Cochrane Library
5. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation
6. Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, place bo-controlled, randomised trial
7. Antidepressant for smoking cessation: (Cochrane review)
8. Bupropion: A review of its use in the management of smoking cessation
9. Long acting beta2-agonists for chronic obstructive pulmonary disease
10. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro
11. Comparison of oral bambuterol and inhaled salmeterol in patients with symptomatic asthma and using inhaled corticosteroids
12. Oral bambuterol compared to inhaled salmeterol in patients with partially reversible chronic obstructive pulmonary disease
13. Tiotropium (Spiriva): Mechanistical considerations and clinical profile in obstructive lung disease
14. The parmacological properties of tiotropium
15. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease
16. Spirometric efficacy of once-daily dosing with tiotropium in stable COPD: A 13-week multicenter trial
17. A randomised con trolled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease
18. 2-adrenoceptor agonists for the modulation of sensory nerves in COPD
19. The effect of multiple doses of Viozan (AR-C68397AA) compared with salbutamol on lung mucociliary clearance and sputum production in patients with COPD
20. The interrelationship of sputum inflammatory markers in patients with chronic bronchitis
21. 4 receptor antagonist LY29311: In vivo pulmonary studies
22. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: The role of leukotriene B4
23. Differences in interleukin-8 and tumor necrosis factor-α in induced sputum from patients with chronic obstructive pulmonary disease or asthma
24. The biology of chemokines and their receptors
25. Peripheral blood mononuclear cell chemotaxis to MCP-1, GRO- and IL-8 in COPD
26. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration
27. Interleukin-8 receptor antagonists in pulmonary diseases
28. Monocyte chemoattractant protein 1, interleukin 8, and chronic airways inflammation in COPD
29. Elevated TNF-alpha production by peripheral blood monocytes of weight-losing COPD patients
30. Infliximab. A review of its use in the management of rheumatoid arthritis
31. Etanercept: A review of its use in rheumatoid arthritis
32. New alpha-substituted succinate-based hydroxamic acids as TNFα convertase inhibitors
33. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers
34. Oxidants/Antioxidants and COPD
35. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double blind, placebo-controlled clinical trials
36. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: Systematic review
37. Antioxidant therapy: A new pharmacological approach in shock, inflammation, and ischemia/reperfusion injury
38. Increase in reactive nitrogen species production in chronic pulmonary disease airways
39. Inhibition of nitric oxide synthase as a potential therapeutic target
40. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial
41. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking
42. Randomised, double-blind placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease; the ISOLDE trial
43. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease
44. Inhaled corticosteroids are not helpful in chronic obstructive pulmonary disease
45. Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD
46. Effects of high dose inhaled steroid on cells, cytokines and proteases in induced sputum in chronic obstructive pulmonary disease
47. No effects of inhaled budesonide on the response to inhaled ozone in normal subjects
48. Cigarette smoking reduces his tone deacetylase 2 expression, enhanced cytokine expression and inhibits glucocorticoid actions in alveolar macrophages
49. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors
50. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic
51. Kinase regulation in inflammatory response
52. Differential IKK activation and IkBa degradation by interleukin-1b and tumor necrosis factor-α in human U937 monocytic cells: Evidence for additional regulatory steps in κB-dependent transduction
53. Inhibition of adhesion of human neutrophils and eosinophils to P-selectin by the sialyl Lewis antagonist TBC1269: Preferential activity against neutrophil adhesion in vitro
54. Enhanced neutrophil response in chronic obstructive pulmonary disease
55. Interleukin-10 level in sputum is reduced in bronchial asthma, COPD and in smokers
56. Recombinant human interleukin 10 in the treatment of patients with wild to moderately active Crohn's disease
57. Both Erk and p38 kinases are necessary for cytokine gene transcription
58. p38 MAP kinase and MKK-1 co-operate in the generation of GM-CSF from LPS-stimulated hu man monocytes by an NF-κB-independent mechanism
59. Inhibition of p38 MAP kinase as a therapeutic strategy
60. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung
61. Function of PI-3Kγ in thymocyte development, T cell activation, and neutrophil migration
62. Neutrophils and protease/anti-protease imbalance
63. Matrix metalloproteinases: Matrix degradation and more
64. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages
65. Ongoing airway inflammation in patients with COPD who do not currently smoke
66. Molecular genetics of chronic obstructive pulmonary disease